

Date: January 06, 2026

To,
The Manager- Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, Block-G,
Bandra - Kurla Complex, Bandra (E), Mumbai
- 400 051

SYMBOL: REMUS

Dear Sir/Madam,

Sub: Disclosure under Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025

In compliance with Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants), Regulations, 2018, please find enclosed herewith the Reconciliation of Share Capital Audit Report, dated January 06, 2026, duly signed and issued by Mr. Tapan Shah, Company Secretary in Practice, for the quarter ended December 31, 2025.

This is for your information and records.

Thanking you.
For, Remus Pharmaceuticals Limited

Deval Patel
Company Secretary and Compliance Officer
ICSI Membership No.: A60090

Encl: As Above

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857

E. remus@remuspharma.com | W. www.remuspharma.com
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536

To,
 The Board of Directors,
REMUS PHARMACEUTICALS LIMITED,
 1101 to 1103, South Tower, One 42,
 B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road,
 Ahmedabad, Gujarat, India, 380054.

RECONCILIATION OF SHARE CAPITAL AUDIT REPORT

CIN : L24232GJ2015PLC084536
 Authorised Capital : Rs. 12,50,00,000

I have examined the Register of Members, beneficiary details given by the Depositories and other records / documents maintained by **M/s. REMUS PHARMACEUTICALS LIMITED**, having its Registered Office at 1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad, Gujarat, India, 380054 for issuing Certificate, in accordance with Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 read with Circular D&CC/FITTC/CIR-16/2002 dated December 31, 2002 issued by the Securities and Exchange Board of India ("SEBI"). To the best of my knowledge and according to the information and explanation given to me and as per the record received through mail and examined by me, I hereby certify that for the quarter ended 31st December, 2025, the details of position of Company's Capital Structure, it's Equity shares position with NSDL, CDSL and in Physical form, Demat activity carried out and any pending Demat status and other details are as under:

1	For Quarter Ended	31/12/2025
2	ISIN	INE005T01011
3	Face Value	Rs. 10/- per Share
4	Name of the Company	REMUS PHARMACEUTICALS LIMITED
5	Registered Office Address	1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli Bopal Road, Ahmedabad, Gujarat, India, 380054.
6	Correspondence Address	-- Same as above --
7	Telephone & Fax Nos.	Tel. 079-29999857
8	Email Address	cs@remuspharma.com legal@remuspharma.com
9	Name of the Stock Exchanges where the Company's Securities are listed with scrip code	National Stock Exchange of India Ltd.- SME emerge platform (Symbol- REMUS)
10	Issued Equity Share Capital	No. of Shares 1,17,84,000
11	Listed Equity Capital (as per company records)	1,17,84,000



		No. of shares		% of issued Capital			
12	Held in dematerialized form in NSDL		18,45,500		15.66		
13	Held in dematerialized form in CDSL		99,38,500		84.34		
14	Physical		0		0.00		
15	Total No. of Shares (12+13+14)		1,17,84,000		100.00		
16	Reason for difference, if any, between (10&11),(11 & 15)		N.A.				
17	Certifying details of changes in share capital during the quarter under consideration as per Table below :						
Particulars		No. of Shares	Applied/ not Applied for Listing	Listed on Stock Exchanges (Specify Names)	Whether intimate d to CDSL	Whether intimated to NSDL	In-principle Approval Pending for SE (Specify Names)
-- N.A. --							
18	Register of Members is updated (YES/NO) if not, updated up to which date				Yes		
19	Reference of previous quarter with regards to excess dematerialized shares, if any				-- N.A. --		
20	Has the company resolved the matter mentioned in point no. 19 above in the current quarter? If not, reason why?				-- N.A. --		
21	Mentioned the total no. of requests, confirmed after 21 days and the total no. of requests pending beyond 21 days(in both cases, from the date of DRN & confirmed by the Registrar is taken), with the reasons for delay :						
Total No. of demat requests			No. of requests		No. of shares		Reasons for delay
			NSDL	CDSL	NSDL	CDSL	N.A.
Confirmed after 21 days			--	--	--	--	
Pending for more than 21 Days			--	--	--	--	
22	Name, Telephone & Fax No. of Compliance Officer of the Co.			Ms. Deval Patel, Company Secretary and Compliance officer Tel : 079-2999 9857 Email : cs@remuspharma.com			
23	Name, Address, Tel. & Fax No. of the Company Secretary in whole-time practice			Mr. Tapan Shah (CP No.2839) 816-818, Anand Mangal-3, Nr. Doctor House, Ellisbridge, Ahmedabad-6 Tel.: 40024320 E-mail : info@tapanshah.in			



24	Appointment of Common Agency for Share Registry Work (Name & Address)	MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited) 5th Floor, 506 to 508, Amarnath Business Centre – I (ABC - I), Nr. St. Xavier's College Corner, Off. C.G.Road, Navrangpura, Ahmedabad- 380009 Tel-079-26465179. E-mail : investor.helpdesk@in.mpms.mufig.com
25	Any other detail that the Co. Secretary may like to provide (e.g. BIFR Co., delisting from SE, Company changed its name etc.	<ul style="list-style-type: none"> During the period, the Company has opened its branch office in Singapore named "Remus Pharmaceuticals (Singapore Branch)". The Board has approved 1st Interim Dividend of Rs. 0.50 (Fifty paise only) per equity share of face value of Rs. 10/- (Rupees Ten only) each fully paid up for the F. Y. 2025-26, as approved by Board in their meeting held on November 10, 2025. Members of the Company, through Postal ballot, have approved Material Related Party Transaction between Espee Biopharma & Finechem LLC ("EBFL") with Rise Pharma LLC ("RPL") (Ordinary Resolution), to the extent of Rs.100 Crores.

Place: Ahmedabad.
Date : 06/01/2026

TAPAN
RAJNIKANT
Signature: SHAH
Name of Company Secretary: TAPAN SHAH
C. P. Number: 2839
UDIN: F004476G003157989

Digitally signed by
TAPAN RAJNIKANT
SHAH
Date: 2026.01.06
17:12:12 +05'30'

Note:

Above report was prepared based on the softcopy of the papers/ report/ documents provided by the Share Registry of the Company, i.e. MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited).

